Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 8/20 | 0.41 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.35 |
| ▸ | HLCS | P50747 | 2/20 | 0.34 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23734257 | 1.00 | F2 (0.41) | F2PLCD1HLCSFUT5PRSS1 | |
| SCHEMBL23734383 | 0.92 | F2 (0.38) | F2PLCD1HLCSPRSS1PRSS2 | |
| SCHEMBL21786782 | 0.86 | F2 (0.54) | F2HLCSFUT5KRAS | |
| SCHEMBL21786783 | 0.86 | F2 (0.54) | F2HLCSFUT5KRAS | |
| SCHEMBL19662403 | 0.86 | F2 (0.54) | F2HLCSFUT5KRAS | |
| SCHEMBL23734500 | 0.84 | FUT5 (0.38) | FUT5KRAS | |
| SCHEMBL21786895 | 0.83 | POLG (0.45) | F2PLCD1HLCSPRSS1PRSS2 | |
| SCHEMBL21786890 | 0.83 | POLG (0.45) | F2PLCD1HLCSPRSS1PRSS2 | |
| SCHEMBL19662094 | 0.83 | POLG (0.45) | F2PLCD1HLCSPRSS1PRSS2 | |
| SCHEMBL21787064 | 0.82 | F2 (0.48) | F2PLCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLL, POLQ, POLB | F2 1573/4885PLCD1 3384/4885HLCS 608/4885 |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | F2 2627/4885PLCD1 3627/4885HLCS 403/4885 |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | F2 2899/4885PLCD1 3495/4885HLCS 318/4885 |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLRMT, RNGTT, MTR | F2 2899/4885PLCD1 3495/4885HLCS 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.